...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Email this morning

The other thought of a bit of hope for Zenith is that Newsoara made the milestone payment of $5 million USD on the completion of the zen3694 phase 2 trial. Although this is a small investment, having read the profiles of the Newsoara team they seem to to be well educated and to have a lot of experience. I would expect that they have done their due diligence and will not suffer fools (hopefully).

GLTA

Toinv

Share
New Message
Please login to post a reply